Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
seizures
Biotech
Bright Minds anti-seizure candidate shines in phase 2 win
The New York-based biotech’s serotonin mimic BMB-101 significantly reduced the number of seizures in patients with absence seizures and epilepsies.
Darren Incorvaia
Jan 6, 2026 10:38am
Praxis sees success in ph. 2 seizure trial, setting up FDA push
Dec 5, 2025 10:00am
Ceribell nets FDA nod for detecting seizures in preterm newborns
Nov 26, 2025 9:49am
Rapport's seizure drug hits in phase 2, sending stock soaring
Sep 8, 2025 8:25am
Praxis' drug reduces seizures but sees 23% discontinuation rate
Aug 4, 2025 10:22am
Why now was the time for Ceribell’s upsized IPO
Oct 15, 2024 4:00pm
